Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.67 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13574067 | 1.00 | CHRM2 (0.70) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL13574070 | 1.00 | CHRM2 (0.70) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL5667254 | 0.99 | ALDH1A1 (0.70) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL3913293 | 0.99 | ALDH1A1 (0.70) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL13266147 | 0.88 | POLB (0.76) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL4200385 | 0.87 | ALDH1A1 (0.55) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL13241387 | 0.86 | CHRM2 (0.78) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL13241377 | 0.85 | CHRM2 (0.77) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL2760340 | 0.85 | CHRM2 (0.73) | CHRM2CHRM1KCNH2SLC6A3POLB | |
| SCHEMBL1610849 | 0.85 | KEAP1 (0.68) | CHRM2CHRM1KCNH2SLC6A3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449173-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | ALLERGAN SALES, LLC (US) | 2019-10-22 | — | — | US | claimed |
| EP-3287122-B1 | DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. | ALLERGAN SALES LLC (US) | 2019-04-17 | — | — | EP | claimed |
| EP-3287122-A1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Allergan Sales, LLC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2427172-B1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | ALLERGAN SALES LLC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160128963-A1 | METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | WATSON LABORATORIES, INC. | 2016-05-12 | — | — | US | claimed |
| US-9259388-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | WATSON PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-8920392-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | WATSON LABORATORIES, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20140046275-A1 | Method for Treating Overactive Bladders and a Device for Storage and Administration of Topical Oxybutynin Compositions | WATSON LABORATORIES, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2427172-A2 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Watson Laboratories, Inc. (US) | 2012-03-14 | — | — | EP | claimed |
| WO-2010129498-A2 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | WATSON LABORATORIES, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| US-20100286630-A1 | Method For Treating Overactive Bladders And A Device For Storage And Administration Of Topical Oxybutynin Compositions | WATSON LABORATORIES, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-10449173-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | ALLERGAN SALES, LLC (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3287122-B1 | DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. | ALLERGAN SALES LLC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3287122-A1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Allergan Sales, LLC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2427172-B1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | ALLERGAN SALES LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-6777576-B2 | NOVEL 2-(2'-CYCLOHEXEN-1'-YL)-2-HYDROXY- 2-PHENYLACETIC ACID ESTER OBTAINED BY REACTING CYCLOHEXENE AND BENZOYLFORMIC ACID ESTER IN PRESENCE OF A LEWIS ACID IS HYDROLYZED AND REDUCED TO GIVE 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETIC ACID | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20030013911-A1 | Production method of 2-cyclohexyl- 2-hydroxy-2-phenylacetic acid intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-1205464-A2 | Production method of 2-cyclohexyl-2-hydroxy-2-phenylacetic acid intermediate therefor and production method thereof | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6060485-A | UROGENITAL DISORDERS | SSP CO., LTD. (JP) | 2000-05-09 | — | — | US | disclosed |
| EP-0913393-A2 | Arylacetic amide derivative or salt thereof, and pharmaceutical comprising it | SSP Co., Ltd. (JP) | 1999-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013911-A1 | Production method of 2-cyclohexyl- 2-hydroxy-2-phenylacetic acid intermediate therefor and production method thereof | HCAR2, HACL2, HADHB | CHRM2 3181/4885CHRM1 3986/4885KCNH2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.